BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 2063854)

  • 1. Recombinant human erythropoietin to correct uremic bleeding.
    Viganò G; Benigni A; Mendogni D; Mingardi G; Mecca G; Remuzzi G
    Am J Kidney Dis; 1991 Jul; 18(1):44-9. PubMed ID: 2063854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of recombinant human erythropoietin on hemostatic status in chronic uremic patients.
    Tsao CJ; Kao RH; Cheng TY; Huang CC; Chang SL; Lee FN
    Int J Hematol; 1992 Apr; 55(2):197-203. PubMed ID: 1511168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant human erythropoietin treatment improves platelet function in uremic patients.
    Cases A; Escolar G; Reverter JC; Ordinas A; Lopez-Pedret J; Revert L; Castillo R
    Kidney Int; 1992 Sep; 42(3):668-72. PubMed ID: 1405344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant human erythropoietin shortens the bleeding time and corrects the abnormal platelet aggregation in hemodialysis patients.
    el-Shahawy MA; Francis R; Akmal M; Massry SG
    Clin Nephrol; 1994 May; 41(5):308-13. PubMed ID: 8050212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Platelet aggregation during the recombinant human erythropoietin (rHuEPO) treatment of patients with uremia].
    Mazerska M; Pawlak K; Azzadin A; Małyszko J; Małyszko J; Myśliwiec M; Buczko W
    Pol Arch Med Wewn; 1992 Oct; 88(4):230-7. PubMed ID: 1488323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A study of platelet functions, some hemostatic and fibrinolytic parameters in relation to serotonin in hemodialyzed patients under erythropoietin therapy.
    Malyszko J; Malyszko JS; Borawski J; Rydzewski A; Kalinowski M; Azzadin A; Mysliwiec M; Buczko W
    Thromb Res; 1995 Jan; 77(2):133-43. PubMed ID: 7740505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of uremic anemia with recombinant erythropoietin also reduces the defects in platelet adhesion and aggregation caused by uremic plasma.
    Zwaginga JJ; IJsseldijk MJ; de Groot PG; Kooistra M; Vos J; van Es A; Koomans HA; Struyvenberg A; Sixma JJ
    Thromb Haemost; 1991 Dec; 66(6):638-47. PubMed ID: 1665596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of recombinant human erythropoietin and correction of anemia on platelet function in hemodialysis patients.
    Akizawa T; Kinugasa E; Kitaoka T; Koshikawa S
    Nephron; 1991; 58(4):400-6. PubMed ID: 1922603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improvement in the haemostatic defect of uraemia after treatment with recombinant human erythropoietin.
    Moia M; Mannucci PM; Vizzotto L; Casati S; Cattaneo M; Ponticelli C
    Lancet; 1987 Nov; 2(8570):1227-9. PubMed ID: 2890852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant human erythropoietin shortens the uraemic bleeding time without causing intravascular haemostatic activation.
    Gordge MP; Leaker B; Patel A; Oviasu E; Cameron JS; Neild GH
    Thromb Res; 1990 Jan; 57(2):171-82. PubMed ID: 2315882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A therapeutical approach by administering reduced glutathione to patients with uremic anemia].
    Xia N; Qu S
    Hua Xi Yi Ke Da Xue Xue Bao; 2001 Jun; 32(2):300-2. PubMed ID: 12600115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of recombinant human erythropoietin on hematological and hemostatic parameters with special reference to microhemolysis.
    Maurin N; Fitzner S; Fritz H; Gladziwa U; H agel J; Stefanidis I
    Clin Nephrol; 1995 Mar; 43(3):196-200. PubMed ID: 7774078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serotonergic mechanisms are involved in the hemostatic action of erythropoietin in uremic patients.
    Malyszko J; Mazerska M; Malyszko J; Pawlak K; Azzadin A; Mysliwiec M; Buczko W
    Int J Clin Lab Res; 1993; 23(1):42-4. PubMed ID: 8477092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of the anemia of predialysis patients with recombinant human erythropoietin: a randomized, placebo-controlled trial.
    Stone WJ; Graber SE; Krantz SB; Dessypris EN; O'Neil VL; Olsen NJ; Pincus TP
    Am J Med Sci; 1988 Sep; 296(3):171-9. PubMed ID: 3177433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hematocrit and bleeding time: an update.
    Anand A; Feffer SE
    South Med J; 1994 Mar; 87(3):299-301. PubMed ID: 8134848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effects of the treatment with human recombinant erythropoietin on primary hemostasis in uremic patients].
    Cases A; Escolar G; Reverter JC; Garrido M; Ordinas A; López-Pedret J; Castillo R; Revert L
    Med Clin (Barc); 1990 Nov; 95(17):644-7. PubMed ID: 2089202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of recombinant human erythropoietin treatment on circulating reticulated platelets in uremic patients: association with early improvement in platelet function.
    Tàssies D; Reverter JC; Cases A; Calls J; Escolar G; Ordinas A
    Am J Hematol; 1998 Oct; 59(2):105-9. PubMed ID: 9766793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular hemodynamic effects of correction of anemia of chronic renal failure with recombinant-human erythropoietin.
    Schwartz AB; Prior JE; Mintz GS; Kim KE; Kahn SB
    Transplant Proc; 1991 Apr; 23(2):1827-30. PubMed ID: 2053168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Human recombinant erythropoietin in treatment of uremic anemia in children with continual ambulatory peritoneal dialysis].
    Litwin M; Boguszewska-Baczkowska A; Jelonek A
    Pol Tyg Lek; 1994 Feb 7-14; 49(6-7):135-6. PubMed ID: 8090665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and blood rheologic stability in erythropoietin-treated predialysis patients.
    Brown CD; Friedman EA
    Am J Nephrol; 1990; 10 Suppl 2():29-33. PubMed ID: 2260615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.